Champignon Brands Announces New CFO and New General Counsel

Appointments Complete New Top Management Team Under
Leadership of Chairman and CEO Dr. Roger McIntyre

Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) Chairman and CEO Roger McIntyre today announced the Company's appointment of Stephen R. Brooks as its new Chief Financial Officer and Peter Rizakos as the firm's new General Counsel.

These appointments complete the Company's new top management team put into place by Dr. McIntyre and the Champignon Board of Directors.  Dr. McIntyre stated, "these new management additions ready us for the future where the Company's clinical products and services will help meet the enormous public need that is creating significant public demand for improved, ketamine-based treatments that are capable of rapid response in persons with depression."

Interim CFO Chris Hobbs , named to that position on December 8, 2020 , pending the recruitment of a new CFO, remains with the Company as special adviser to Mr. Brooks concerning the British Columbia Securities Commission (BCSC) continuous disclosure review and cease trade order (CTO).

Dr. McIntyre applauded Mr. Hobbs "leadership, competence and professionalism" in taking over these duties on an interim basis in a complete and cooperative response to the BCSC process.

The Company's growth strategy is international in scope and is proceeding even while the Company works with the BCSC toward conclusion of the continuous disclosure review, the lifting of the CTO and the resumption of trading of the Company's securities on the Canadian Securities Exchange.

Dr. McIntyre said Champignon's depression clinic network continues to emerge with current and imminent openings of treatment centres in Toronto , Ottawa , and Montreal . The expansion of the network will continue through Champignon's Canadian Rapid Treatment Centre of Excellence (CRTCE).

Chief Financial Officer, Stephen R. Brooks
Stephen Brooks is a seasoned finance professional with over 25 years experience across a range of industries including telecommunications, sports, entertainment, media, and retail.

Mr. Brooks was formerly Chief Financial Officer of Sim International, a television and movie service provider, CFO of the Ottawa Senators NHL hockey club and Senior Vice-President, Business Operations, of the Toronto Blue Jays and Rogers Centre.

Prior to this, Mr. Brooks spent several years in senior finance roles with Rogers Communications Inc. and Rogers Media Inc., including having responsibility for US and Canadian public reporting requirements.

General Counsel, Peter Rizakos
Peter Rizakos brings to the position of General Counsel 30 years of experience as a corporate and securities lawyer and as an executive in a variety of roles in both established and early-stage businesses.

Most recently, Mr. Rizakos was President and CEO of a private mining company and General Counsel for Marret Asset Management Inc., a Canadian asset manager. He was also top legal officer for one of Canada's leading investment fund companies.

Peter has extensive experience with both public and private companies, including implementation of growth strategies, capital-raising and asset acquisition, legal and regulatory compliance and on board and governance matters.

Professional Affiliations
Stephen Brooks served 10 years in public practice with Deloitte & Touche, LLP in Vancouver , UK, and New York . He is a Chartered Accountant and Chartered Professional Accountant in Ontario and BC and an alumnus of the University of British Columbia and Harvard Business School .

Peter Rizakos articled and practiced law at Blakes in Toronto . He is a member of the Law Society of Ontario , has an MBA from INSEAD and LLB from Osgoode Hall Law School.

Champignon Brands Inc. ( https://champignonbrands.com ) is a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions. The Company works closely with subsidiaries including AltMed Capital Corp. ("AltMed"). The Canadian Rapid Treatment Center of Excellence is wholly owned by AltMed.

ON BEHALF OF THE BOARD
" Dr. Roger McIntyre "
Dr. Roger McIntyre
Chairman & CEO

Call emergency medical services immediately if you believe you are experiencing a medical emergency. Do not rely on communication through the Champignon Brands website of the emails/telephone numbers above for urgent medical needs. Champignon Brands Inc. does not provide medical advice. If you have any specific medical questions or are seeking advice, please consult with your health care provider.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/champignon-brands-announces-new-cfo-and-new-general-counsel-301204721.html

SOURCE Champignon Brands Inc.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Q4 Fiscal 2025 Highlights Revenue of $2.3 million, a 29.0% increase over Q3 2025 Gross profit of $1.4 million, compared to a gross profit of $0.8 million in Q3 2025 Cash position of $0.5 million as of August 31, 2025 Subsequent to Quarter End On April 18, 2026, President Donald Trump signed an... Keep Reading...
The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

Brisbane, Australia - The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, is pleased to announce the execution of an Exclusive Distribution Agreement with a... Keep Reading...
Gloved hand holds a cluster of brown mushrooms growing from a gray substrate block.

Psychedelics Market Trends: H1 2026 Review and Forecast

The psychedelic medicine market is moving swiftly from speculative research mode toward an institutional, prescription-oriented framework as federal policy in the US becomes more supportive.President Donald Trump’s April 18 executive order on ibogaine and other psychedelic therapies helped... Keep Reading...
A pill bottle with US flag and coloured pills.

Medical Cannabis and Psychedelics Reforms Reshaping Mental Health Markets

The landscape for medical cannabis and psychedelic therapies has rapidly shifted in just a few weeks following recent executive actions in the US. Between the formal rescheduling of medical cannabis to Schedule III and an executive order aimed at accelerating mental health treatments, several... Keep Reading...
Dried mushrooms surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, but Risks Remain

On April 18, US President Donald Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments for Serious Mental Illness, an executive order (EO) to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as... Keep Reading...
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...

Interactive Chart

Latest Press Releases

Related News